AsepticSure™ Hospital Sterilization System Demonstrates Total Eradication of Super Bugs. (Comments Off)
San Francisco, California February 4, 2010, Medizone International, Inc. (MZEI.OB) announced today that every full scale test run completed thus far in its hospital room mock up facility has resulted in the total elimination of all bacteria present in the room.
In this current phase of development, Medizone’s scientific team will attempt to confirm, in [...]
Medizone International News
February 6, 2010
Let me start by wishing everyone an excellent 2010. Medizone reached milestones during 2009 relative to the AsepticSure™ development program that sets the pulse not only for a very successful 2010, but I believe has laid the foundation for achieving full commercialization in the area of hospital sterilization and critical infrastructure clean up in addition to the exceedingly strong likelihood of contributing greatly in the area of bio-terrorism counter measures. These are two distinct avenues of revenue production, both with an increasingly high likelihood of commercial success.
I would like to acknowledge the tremendous level of leadership skill that has been demonstrated by Dr. Michael Shannon, one of Medizone’s Board Members and our Director of Medical Affairs. Michael has been instrumental in the building of a research and development team that may be un-paralleled for a company of Medizone’s size. The accomplishment this group of esteemed men has achieved is remarkable. To repeatedly and predictably be able to achieve 6 log (99.9999%) sterilization standards of bactericidal kill across the full spectrum of bacteria we have worked with in open space settings is unprecedented. It is amazing to me that our development team has reached these previously unachievable levels of scientific success in only one year. A year ago initial conversations were in the works with those who are now our key people about the possibility of developing equipment to help rid hospitals of HAIs, and the science we thought it would take to reach that goal. We had no equipment, nor a laboratory, but together we did bring a wealth of experience, knowledge, ideas and a team of incredibly talented bright people that were destined to find a synergy, a magic, in working together on a unique project. Today, we have three highly successful laboratory trials behind us and a full scale hospital mock up trial in progress, which has already demonstrated our equipment will deliver as promised in the field, and two new patent applications filed for commercial protection. What a difference one year has made! Remarkable!
In recapping our work in 2009 that set the agenda for moving forward from where we are today, let me start by broadly reviewing the steps that have brought us to this present stage. In the first round of trials, working just with ozone as the primary agent, we achieved in the area of 3 log (99.9%) to 4 log (99.99%) of bactericidal reductions on average. For the second round of trials our “formula” was tweaked a little bit, and the results improved by a log on average, putting us solidly in the 4 log to 5 log range. With an impressive amount of data logging achieved, and following a thorough search of the patent literature by two patent firms, our first patent application was filed for AsepticSure™ July 6, 2009 titled “Healthcare Facility Disinfecting System” US application 61/223,219. That filing made three distinct and unique claims based not only on inventive engineering design and protocols, but backed up with solid scientific evidence that was demonstrated to be repeatable. This patent protects the Company’s basic disinfectant procedure and protocol, involving the use of ozone-containing atmosphere, and the apparatus used for implementing it.
For the third round of trials recently completed, an additional technology was integrated that catapulted AsepticSure™ to the accepted sterilization standard of 6 logs or greater (99.9999% bactericidal kill.) This result is phenomenal in that Medizone is the only company in the world known to have reached this standard, and it has done so using a product that is portable, affordable and is now proving capable of full room sterilization with a turn around time of 2 hours or less for re-use, while not damaging electronics and other built in infrastructure within the room.
The actual measured numbers of bactericidal reduction from the completed third round of laboratory trials when compared to the larger samples were >6.5 log for C difficile, >7 log for MRSA, 7 log for E-coli, 6.6 Log for VRE, 7 log for Pseudomonas aeruginous and > 7 log for Bacillus subtilis. Given this unprecedented scientific data and the protocols compiled as part of the patent applications, in combination with the uniqueness of the invention itself, gives Medizone every confidence that our patent protection will stand firm and strong and protect the commercial rights of shareholders well into the future as Medizone transitions to a revenue producing company.
A second patent filing for AsepticSure™ was announced on January 20, 2010 titled “Disinfecting Process and Apparatus” US application 61/295,851. This protects improvements in the Company’s basic procedure and protocol achieved by combining it with another procedure, resulting in a significant increase in disinfecting capabilities demonstrated during the third round of laboratory trials against a wide variety of bacteria and on a range of different surfaces commonly found in healthcare and other essential facilities. Both patent applications currently afford international protection for this technology, and can be expanded into full international patent applications, in countries of the Company’s choice, in the months ahead.
On February 4th 2010 Medizone announced a successful progression to full room scale testing, achieving total eradication (>6 logs) with all bacteria tested to date (MRSA, VRE and E coli) on every single run. Additional testing now underway with the remaining causative agents of HAIs, are expected to replicate the results achieved in our small laboratory test unit with the remaining bacteria, just as these early mock trial results have already proven. It was stated in the February 4 th press release, “It now seems certain that AsepticSure™ will deliver as promised.” It is a simple statement, but absolutely true!
2010 is clearly starting out as great year for Medizone International. I believe it will prove to be a year of dramatic transition, accomplishment and reward. The goal of becoming a significant revenue producing company is progressing toward reality with an historic scientific product that we believe is strongly protected intellectually. When the mock trials currently underway are completed, we expect to then be positioned to move into hospital beta testing at sites in both the United States and Canada. The final step is then expected to be sales and partnering with major corporate partners already fully imbedded in the hospital sector for additional manufacturing, sales and service support. As results are produced in the field in the form of cleaner hospitals and a reduced incident of HAIs, it is assured that product demand will be strong. The potential for Medizone International to now develop into a solid, revenue producing growth company for many years to come is significant. I believe the year 2010 will prove to be historic in our company’s history.
To be able to greatly reduce human suffering, save thousands if not tens of thousands of lives and be able to significantly reduce hospital operating costs all in one broad stroke called AsepticSure™, will truly prove to be a significant achievement in the history of science and medicine. I believe Medizone International is now firmly on the threshold of that achievement. Stand by, I promise you there will be more news to come in the months ahead!
Yours truly,
Edwin G. Marshall
Chairman & CEO
Medizone International, Inc.
This Chairman’s message contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
Annual Shareholder Meeting
Peppermill Hotel and Casino
2707 South Virginia Street
Reno, NV 89502
August 26, 2009, Wednesday at 10:00 A.M.
Entries(RSS)